| Literature DB >> 21308175 |
Lorena Ulhôa Araújo1, Kemile Toledo de Albuquerque, Kelly Cristina Kato, Gleiciely Santos Silveira, Náira Rezende Maciel, Pollyanna Álvaro Spósito, Neila Márcia Silva Barcellos, Jacqueline de Souza, Márcia Bueno, Sílvia Storpirtis.
Abstract
The Brazilian generic drugs policy was implemented in 1999 with the aim of stimulating competition in the market, improve the quality of drugs and improve the access of the population to drug treatment. The process of implementing this policy allowed the introduction and discussion of concepts that had never before been used in the context of drug registration in Brazil: bioavailability, bioequivalence, pharmaceutical equivalence, generic drugs, biopharmaceutical classification system, biowaiver. The present article provides definitions for these concepts in the context of Brazilian legislation as well as a historical and chronological description of the implementation of the generic drugs policy in Brazil, including a list of current generic drug legislation. This article contributes to the understanding of the Brazilian generic drugs policy and facilitates the search for information concerning the legal requirements for registration of drugs in Brazil.Mesh:
Substances:
Year: 2010 PMID: 21308175 DOI: 10.1590/s1020-49892010001200010
Source DB: PubMed Journal: Rev Panam Salud Publica ISSN: 1020-4989